Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 12/20 | 1.00 |
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25276800 | 1.00 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL12196053 | 1.00 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL14012024 | 1.00 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25272649 | 1.00 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL421217 | 1.00 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25229283 | 1.00 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25270743 | 1.00 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL1753630 | 0.98 | EPHX1 (0.95) | EPHX1CASP2EPHX2 | |
| SCHEMBL25225195 | 0.95 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25225212 | 0.95 | EPHX1 (1.00) | EPHX1CASP2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| EP-0378657-B1 | OXAZOLIDINONE PENETRATION ENHANCING COMPOUNDS | RAJADHYAKSHA VITHAL J (US) | 1994-02-02 | — | — | EP | disclosed |
| US-4960771-A | TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS; DRUGS, SUNSCREENS, INSECT REPELLENTS, COSMETICS | LVMH MOET HENNESSY LOUIS VUITTON, INC. | 1990-10-02 | — | — | US | disclosed |
| EP-0378657-A1 | OXAZOLIDINONE PENETRATION ENHANCING COMPOUNDS. | RAJADHYAKSHA VITHAL J | 1990-07-25 | — | — | EP | disclosed |
| WO-1990000407-A1 | OXAZOLIDINONE PENETRATION ENHANCING COMPOUNDS | RAJADHYAKSHA VITHAL J (US) | 1990-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885CASP2 4504/4885EPHX2 2/4885 |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | EPHX1, LTA4H, PTGS1 | EPHX1 1/4885CASP2 2397/4885EPHX2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.